Surgery Partners Sells Idaho Hospitals in Major Strategic Shift

Well, it’s official: Surgery Partners Inc. (NASDAQ: SGRY), headquartered in Brentwood, Tennessee, has successfully closed a pretty substantial deal. The company announced on September 17, 2026, that it had completed the divestment of its Idaho Falls-based facilities – specifically, Mountain View Hospital and Idaho Falls Community Hospital – to Intermountain Health. This isn't just a simple transaction; it's a strategic maneuver that significantly reshapes Surgery Partners' operational landscape and financial health.

This whole process kicked off back in July when the agreement was first announced on the 24th, though some sources pinpoint the initial news closer to the 21st. Fast forward to mid-September, and the ink is dry. Surgery Partners walked away with a tidy sum, bringing in $797 million in gross proceeds. After accounting for all the usual adjustments, they pocketed an impressive $587 million in net cash at closing. What's the plan for all that cash, you ask? Primarily, it’s earmarked to pay down debt, which is always a smart move for a company looking to shore up its balance sheet.

Now, let's talk numbers and why this deal looks particularly attractive for Surgery Partners. The proceeds, if you dig into the financials, represent about a 7x multiple on the facilities' adjusted EBITDA over the last twelve months ending June 30, 2026. If you look at it from the perspective of average distributions received over the past three years, it's an even more eye-popping 17x multiple. So, from a valuation standpoint, it seems like SGRY got a pretty good price for these assets. In fact, this divestment is expected to trim their balance sheet leverage by a solid 30 basis points, bringing it down from 4.4x at the close of the second quarter of 2026.

Eric Evans, the CEO of Surgery Partners, was quite clear about the intent behind this sale. It's all about streamlining and focusing on what they do best: surgical services. Shedding these Idaho Falls hospitals means the company can really lean into its core strategy. From an operational perspective, this is a dramatic shift. We’re talking about a 50% reduction in their Medicaid payor mix, dropping it to under 2% of total revenue. They're also completely exiting service lines like neonatology and obstetrics, reducing intensive care beds by half, and cutting non-surgical admissions by a significant 75%. Inpatient pediatrics and retail pharmacy services are out the door too. This move fundamentally alters the mix of services Surgery Partners offers, making it much more specialized.

It's worth noting that while Intermountain Health is now at the helm of Mountain View Hospital, the physician ownership structure there will remain untouched. This ensures continuity and familiarity for the local medical community, which is often a key consideration in such large-scale transitions. For Surgery Partners, however, the updated full-year 2026 guidance reflects these significant changes. They're now projecting revenue between $3.08 billion and $3.18 billion, with adjusted EBITDA expected to hit at least $489 million for the full year. Looking at it pro forma, without the Idaho Falls facilities, their revenue is anticipated to be in the range of $2.60 billion to $2.67 billion, and adjusted EBITDA at least $414 million. Clearly, this is a leaner, more surgically-focused operation moving forward.

The deal had its share of financial heavy hitters too. Barclays served as the lead financial advisor for Surgery Partners, guiding them through the intricacies of the sale. On Intermountain Health's side, RBC Capital Markets provided advisory support. In essence, this divestment isn't just a financial transaction; it’s a strategic pivot, allowing Surgery Partners to shed non-core assets, significantly reduce debt, and sharpen its focus on its specialized surgical platform. It’s a bold move, and certainly one to watch as the company charts its future course.